Skip to main content
OpenTrials
Completed

NCT Number: NCT01908426

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hepatocellular Carcinoma Adenocarcinoma Carcinoma Carcinoma, Hepatocellular Digestive System Diseases Digestive System Neoplasms Liver Diseases Liver Neoplasms Neoplasms Neoplasms by Histologic Type Neoplasms by Site Neoplasms, Glandular and Epithelial

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Camperdown, New South Wales, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Select Inclusion Criteria:

  • Histological or cytological diagnosis of HCC.
  • The subject has disease that is not amenable to a curative treatment approach.
  • Received prior sorafenib.
  • Progression following at least 1 prior systemic treatment for HCC.
  • Recovery to from toxicities related to any prior treatments.
  • ECOG performance status of 0 or 1.
  • Adequate hematologic and renal function, based upon meeting protocol defined laboratory criteria within 7 days before randomization.
  • Child-Pugh Score of A.
  • Antiviral therapy per local standard of care if active hepatitis B (HBV) infection.
  • Sexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for 4 months after the last dose of study treatment.
  • Female subjects of childbearing potential must not be pregnant at screening.

Select Exclusion Criteria:

  • Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.
  • Receipt of more than 2 prior systemic therapies for advanced HCC.
  • Any type of anticancer agent (including investigational) within 2 weeks before randomization.
  • Radiation therapy within 4 weeks (2 weeks for radiation for bone metastases) or radionuclide treatment within 6 weeks of randomization.
  • Prior cabozantinib treatment.
  • Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.
  • Concomitant anticoagulation, at therapeutic doses, with anticoagulants.
  • Serious illness other than cancer that would preclude safe participation in the study.
  • Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding.
  • Moderate or severe ascites.
  • Pregnant or lactating females.
  • Diagnosis of another malignancy within 2 years before randomization, except for superficial skin cancers, or localized, low-grade tumors.

Treatment and study plan

Cabozantinib tablets

Drug

Other names: XL184

Placebo tablets

Drug

Primary outcomes

  1. Overall Survival (OS)

    Time frame: Up to 45 months

    The primary analysis of OS is defined as the time from randomization to death from any cause. The analysis was based on a second planned interim analysis prespecified to be performed at approximately the 75% information fraction (ie, at approximately 466 deaths). The data cutoff date for this event-driven analysis in the Intent to Treat (ITT) population was 01 June 2017. Median OS was calculated using the Kaplan-Meier estimates.

Secondary outcomes

  1. Progression-Free Survival (PFS)

    Time frame: Up to 45 months

    Duration of PFS is defined as the time of randomization to the earlier of the following events, progressive disease as determined by Investigator (per RECIST 1.0, which is defined by a ≥ 20% increase in the sum of the longest diameter of target lesions from baseline) or death due to any cause. A Kaplan- Meier analysis was performed to estimate the median duration.

  2. Objective Response Rate (ORR)

    Time frame: ORR is measured by radiologic assessment every 8 weeks after randomization until disease progression or discontinuation of study treatment (up to 45 months)

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.

Sponsors and collaborators

Lead sponsor

Exelixis

Industry

Registry information

Official study title

A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Acronym: CELESTIAL

Important dates

Study start
2013
Primary completion
2017
Study completion
2021
First posted
Jul 25, 2013
Registry last updated
May 6, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.